Right. So, ImmunityBio (IBRX +41.36%). Closed at $8.54 yesterday. A 41% jump. Honestly, it felt…predictable. The EU gave Anktiva conditional marketing authorization for bladder cancer. Which, let’s be real, is a big deal. They moved 78.5 million shares. That’s…a lot of hope being priced in. They IPO’d in 2015, and have been circling the drain ever since, down 75%. It’s the kind of stock that makes you question all your life choices. I’ve been watching them for a while now, and frankly, it’s been a rollercoaster. A really, really messy rollercoaster.
How the Markets Played Along
The S&P 500 did its usual thing, inching up 0.53% to 6,880. The Nasdaq Composite, ever the optimist, added 0.78%, landing at 22,754. Biotech was…mixed. Iovance Biotherapeutics managed a small gain (+3.82%), while Krystal Biotech decided to take a nap (-1.58%). Honestly, the biotech sector feels like a group therapy session. Everyone’s trying to appear stable, but underneath it all…chaos.
What This Actually Means (For Those Paying Attention)
Okay, so Anktiva. Conditional marketing authorization in Europe. It’s used with BCG, for bladder cancer patients who’ve stopped responding to the usual treatment. Which, let’s be clear, is a big deal for those patients. But for us? It opens up access to over 30 new countries. That’s potential revenue, people. And potential for…well, let’s just say I’ve been quietly accumulating shares. Don’t tell anyone. It’s a bit of a gamble, admittedly. But I like a gamble. Especially when it involves potentially disruptive immunotherapy.
They’re projecting some…ambitious growth. Quadrupling the stock in 2026. 700% sales increase in 2025. Approvals from Saudi Arabia. Promising data on lung cancer. Solid tumor applications. It all sounds fantastic. And I’m not saying it won’t happen. I’m just saying…read the fine print. And maybe, just maybe, have an exit strategy. Because if it doesn’t happen? Well, let’s just say I’ll be having a very awkward conversation with my broker.
Look, Anktiva is promising. Genuinely. But ImmunityBio is still…fragile. Highly dependent on good news. One negative trial, one regulatory hiccup, and this whole thing could come crashing down. So, yes, it’s a volatile stock. But that’s precisely why I’m interested. Because sometimes, the biggest rewards come with the biggest risks. Just…don’t blame me if it all goes south.
Read More
- 2025 Crypto Wallets: Secure, Smart, and Surprisingly Simple!
- Wuchang Fallen Feathers Save File Location on PC
- Gold Rate Forecast
- Brown Dust 2 Mirror Wars (PvP) Tier List – July 2025
- HSR 3.7 breaks Hidden Passages, so here’s a workaround
- Crypto Chaos: Is Your Portfolio Doomed? 😱
- 17 Black Actresses Who Forced Studios to Rewrite “Sassy Best Friend” Lines
- MicroStrategy’s $1.44B Cash Wall: Panic Room or Party Fund? 🎉💰
- The Best Single-Player Games Released in 2025
- Elden Ring’s Fire Giant Has Been Beaten At Level 1 With Only Bare Fists
2026-02-19 01:23